Article
Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy
2026-02-08
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Background</h4> Resistance to immune checkpoint inhibitors represents a major therapeutic challenge, as less than 50% of patients with melanoma achieve long-term response to immune checkpoint inhibitor therapy. One mechanism of acquired resistance involves somatic mutations, such as loss of beta-2 microglobulin ( B2m ), that enable tumor cells to evade T cell-mediated killing. <h4>Methods...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 99dbd377-3334-5ea4-821d-a78f9728a0f2
- DOI
- 10.64898/2026.02.05.704029
